<p>MiMedx Group（纳斯达克代码：MDXG - 获取免费报告）在周六发布的一份报告中被华尔街 Zen 的股票研究人员从 “强力买入” 评级下调至 “买入” 评级。</p>
<p>MDXG 一直是其他多份报告的主题。Weiss Ratings 在 12 月 29 日的研究报告中重申了对 MiMedx Group 股票的 “持有（c）” 评级。Cantor Fitzgerald 在 2 月 17 日的报告中将 MiMedx Group 的目标价格从 12.00 美元下调至 8.00 美元，并对该股票设定了 “增持” 评级。花旗集团在周一的研究报告中开始覆盖 MiMedx Group，并对该股票给予了 “市场表现优于大盘” 的评级。Citizens Jmp 在 2 月 23 日的报告中开始覆盖 MiMedx Group，设定了 “市场表现优于大盘” 的评级和 10.00 美元的价格目标。最后，瑞银集团在周一的研究报告中设定了 MiMedx Group 的 10.00 美元价格目标。五位投资分析师对该股票给予了买入评级，一位给予了持有评级。根据 MarketBeat 的数据，MiMedx Group 的平均评级为 “适度买入”，共识目标价格为 9.60 美元。</p>
<p><strong>获取我们关于 MiMedx Group 的最新研究报告</strong></p>
<h2>MiMedx Group 股票下跌 1.0%</h2>
<p>周五，MiMedx Group 股票开盘价为 4.89 美元。该公司的市值为 7.2422 亿美元，市盈率为 15.28，贝塔值为 1.59。该股票的 50 日简单移动平均为 5.70 美元，200 日简单移动平均为 6.58 美元。MiMedx Group 的 52 周低点为 4.78 美元，52 周高点为 8.46 美元。该公司的债务与股本比率为 0.07，流动比率为 4.41，速动比率为 3.95。</p>
<p>MiMedx Group（纳斯达克代码：MDXG - 获取免费报告）最后一次发布季度财报是在 2 月 25 日，报告显示该季度每股收益（EPS）为 0.14 美元，超出分析师共识预期的 0.09 美元，超出幅度为 0.05 美元。该公司在该季度的收入为 1.181 亿美元，而分析师的预期为 1.0678 亿美元。MiMedx Group 的净利润率为 11.60%，股本回报率为 30.61%。平均而言，股票研究分析师预计 MiMedx Group 在当前财年将发布 0.3 美元的每股收益。</p>
<h2>对 MiMedx Group 的对冲基金看法</h2>
<p>最近，一些对冲基金对该公司的持仓进行了调整。First Light Asset Management LLC 在第三季度将其在 MiMedx Group 的持股增加了 89.5%。First Light Asset Management LLC 现在拥有该公司 3,652,952 股股票，价值 25,498,000 美元，此前在此期间又收购了 1,725,458 股。Nantahala Capital Management LLC 在第三季度获得了 MiMedx Group 的新头寸，价值约为 10,237,000 美元。Marshall Wace LLP 在第四季度将其在 MiMedx Group 的持股增加了 864.9%。Marshall Wace LLP 现在拥有该公司 1,381,288 股股票，价值 9,351,000 美元，此前在此期间又购买了 1,238,132 股。Hillsdale Investment Management Inc.在第四季度获得了 MiMedx Group 的新股份，价值约为 7,134,000 美元。最后，Disciplined Growth Investors Inc. MN 在第三季度将其在 MiMedx Group 的持股增加了 283.0%。Disciplined Growth Investors Inc. MN 现在拥有该公司 1,383,451 股股票，价值 9,656,000 美元，此前在上个季度又购买了 1,022,202 股。机构投资者和对冲基金持有该公司 79.15% 的股票。</p>
<h2>关于 MiMedx Group</h2>
<p>（获取免费报告）</p>
<p>MiMedx Group, Inc 是一家生物制药公司，专注于开发、制造和营销源自人类胎盘组织的再生生物材料产品。该公司的核心使命是利用羊膜和绒毛膜中的细胞外基质和生长因子来支持伤口愈合和外科应用。MiMedx 的产品线利用专有的净化工艺，旨在保留原生组织特性，同时确保无菌和安全。</p>
<p>MiMedx 的主要产品包括以 EpiFix®和 AmnioFix®等名称品牌的羊膜/绒毛膜同种异体移植物，适用于急性和慢性伤口的治疗，包括糖尿病足溃疡、静脉性腿部溃疡和手术部位修复。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票比 MiMedx Group 更好</li>
<li>用这 4 个简单步骤 “防止美联储影响” 你的银行账户</li>
<li>有史以来最大的 IPO……向普通人开放</li>
<li>银价记录很好，月收入更好</li>
<li>阅读此文，否则将永远后悔</li>
<li>卖这个，买那个</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURYRw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURYRw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 MiMedx Group 吗？</h2>
<p>在你考虑 MiMedx Group 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 MiMedx Group 并不在名单上。</p>
<p>虽然 MiMedx Group 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

MDXG

<p>华尔街禅将 MiMedx Group（NASDAQ:MDXG）的评级从 “强力买入” 下调至 “买入”。其他分析师也给出了混合评级，Weiss Ratings 维持 “持有（c）” 评级，而 Cantor Fitzgerald 将目标价格从 12.00 美元下调至 8.00 美元。MiMedx Group 的股票开盘价为 4.89 美元，市值为 7.2422 亿美元。该公司报告每股收益为 0.14 美元，超出预期，营收为 1.181 亿美元。机构投资者持有该股票的 79.15%，该公司专注于用于伤口愈合的再生生物材料产品</p>

<p>MiMedx Group (NASDAQ:MDXG - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a report released on Saturday.</p>
<div class="lb-trans"><p>MiMedx Group（纳斯达克代码：MDXG - 获取免费报告）在周六发布的一份报告中被华尔街 Zen 的股票研究人员从 “强力买入” 评级下调至 “买入” 评级。</p>
</div><p>MDXG has been the topic of a number of other reports. Weiss Ratings reiterated a &#34;hold (c)&#34; rating on shares of MiMedx Group in a research note on Monday, December 29th. Cantor Fitzgerald lowered their target price on MiMedx Group from $12.00 to $8.00 and set an &#34;overweight&#34; rating on the stock in a report on Tuesday, February 17th. Citigroup started coverage on MiMedx Group in a research report on Monday. They issued a &#34;market outperform&#34; rating on the stock. Citizens Jmp started coverage on MiMedx Group in a report on Monday, February 23rd. They set a &#34;market outperform&#34; rating and a $10.00 price target for the company. Finally, UBS Group set a $10.00 price objective on MiMedx Group in a research report on Monday. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, MiMedx Group has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $9.60.</p>
<div class="lb-trans"><p>MDXG 一直是其他多份报告的主题。Weiss Ratings 在 12 月 29 日的研究报告中重申了对 MiMedx Group 股票的 “持有（c）” 评级。Cantor Fitzgerald 在 2 月 17 日的报告中将 MiMedx Group 的目标价格从 12.00 美元下调至 8.00 美元，并对该股票设定了 “增持” 评级。花旗集团在周一的研究报告中开始覆盖 MiMedx Group，并对该股票给予了 “市场表现优于大盘” 的评级。Citizens Jmp 在 2 月 23 日的报告中开始覆盖 MiMedx Group，设定了 “市场表现优于大盘” 的评级和 10.00 美元的价格目标。最后，瑞银集团在周一的研究报告中设定了 MiMedx Group 的 10.00 美元价格目标。五位投资分析师对该股票给予了买入评级，一位给予了持有评级。根据 MarketBeat 的数据，MiMedx Group 的平均评级为 “适度买入”，共识目标价格为 9.60 美元。</p>
</div><p><strong>Get Our Latest Research Report on MiMedx Group</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 MiMedx Group 的最新研究报告</strong></p>
</div><h2>MiMedx Group Stock Down 1.0%</h2>
<div class="lb-trans"><h2>MiMedx Group 股票下跌 1.0%</h2>
</div><p>Shares of MiMedx Group stock opened at $4.89 on Friday. The firm has a market cap of $724.22 million, a price-to-earnings ratio of 15.28 and a beta of 1.59. The stock has a 50-day simple moving average of $5.70 and a 200-day simple moving average of $6.58. MiMedx Group has a 52-week low of $4.78 and a 52-week high of $8.46. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.41 and a quick ratio of 3.95.</p>
<div class="lb-trans"><p>周五，MiMedx Group 股票开盘价为 4.89 美元。该公司的市值为 7.2422 亿美元，市盈率为 15.28，贝塔值为 1.59。该股票的 50 日简单移动平均为 5.70 美元，200 日简单移动平均为 6.58 美元。MiMedx Group 的 52 周低点为 4.78 美元，52 周高点为 8.46 美元。该公司的债务与股本比率为 0.07，流动比率为 4.41，速动比率为 3.95。</p>
</div><p>MiMedx Group (NASDAQ:MDXG - Get Free Report) last issued its quarterly earnings data on Wednesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.09 by $0.05. The firm had revenue of $118.10 million during the quarter, compared to analysts' expectations of $106.78 million. MiMedx Group had a net margin of 11.60% and a return on equity of 30.61%. On average, equities research analysts expect that MiMedx Group will post 0.3 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>MiMedx Group（纳斯达克代码：MDXG - 获取免费报告）最后一次发布季度财报是在 2 月 25 日，报告显示该季度每股收益（EPS）为 0.14 美元，超出分析师共识预期的 0.09 美元，超出幅度为 0.05 美元。该公司在该季度的收入为 1.181 亿美元，而分析师的预期为 1.0678 亿美元。MiMedx Group 的净利润率为 11.60%，股本回报率为 30.61%。平均而言，股票研究分析师预计 MiMedx Group 在当前财年将发布 0.3 美元的每股收益。</p>
</div><h2>Hedge Funds Weigh In On MiMedx Group</h2>
<div class="lb-trans"><h2>对 MiMedx Group 的对冲基金看法</h2>
</div><p>A number of hedge funds have recently made changes to their positions in the business. First Light Asset Management LLC lifted its holdings in shares of MiMedx Group by 89.5% during the 3rd quarter. First Light Asset Management LLC now owns 3,652,952 shares of the company's stock worth $25,498,000 after acquiring an additional 1,725,458 shares during the period. Nantahala Capital Management LLC acquired a new position in MiMedx Group in the third quarter worth about $10,237,000. Marshall Wace LLP lifted its stake in MiMedx Group by 864.9% during the fourth quarter. Marshall Wace LLP now owns 1,381,288 shares of the company's stock worth $9,351,000 after purchasing an additional 1,238,132 shares during the period. Hillsdale Investment Management Inc. acquired a new stake in MiMedx Group during the fourth quarter valued at approximately $7,134,000. Finally, Disciplined Growth Investors Inc. MN boosted its holdings in MiMedx Group by 283.0% during the third quarter. Disciplined Growth Investors Inc. MN now owns 1,383,451 shares of the company's stock valued at $9,656,000 after purchasing an additional 1,022,202 shares in the last quarter. Institutional investors and hedge funds own 79.15% of the company's stock.</p>
<div class="lb-trans"><p>最近，一些对冲基金对该公司的持仓进行了调整。First Light Asset Management LLC 在第三季度将其在 MiMedx Group 的持股增加了 89.5%。First Light Asset Management LLC 现在拥有该公司 3,652,952 股股票，价值 25,498,000 美元，此前在此期间又收购了 1,725,458 股。Nantahala Capital Management LLC 在第三季度获得了 MiMedx Group 的新头寸，价值约为 10,237,000 美元。Marshall Wace LLP 在第四季度将其在 MiMedx Group 的持股增加了 864.9%。Marshall Wace LLP 现在拥有该公司 1,381,288 股股票，价值 9,351,000 美元，此前在此期间又购买了 1,238,132 股。Hillsdale Investment Management Inc.在第四季度获得了 MiMedx Group 的新股份，价值约为 7,134,000 美元。最后，Disciplined Growth Investors Inc. MN 在第三季度将其在 MiMedx Group 的持股增加了 283.0%。Disciplined Growth Investors Inc. MN 现在拥有该公司 1,383,451 股股票，价值 9,656,000 美元，此前在上个季度又购买了 1,022,202 股。机构投资者和对冲基金持有该公司 79.15% 的股票。</p>
</div><h2>About MiMedx Group</h2>
<div class="lb-trans"><h2>关于 MiMedx Group</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company's core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx's product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.</p>
<div class="lb-trans"><p>MiMedx Group, Inc 是一家生物制药公司，专注于开发、制造和营销源自人类胎盘组织的再生生物材料产品。该公司的核心使命是利用羊膜和绒毛膜中的细胞外基质和生长因子来支持伤口愈合和外科应用。MiMedx 的产品线利用专有的净化工艺，旨在保留原生组织特性，同时确保无菌和安全。</p>
</div><p>MiMedx's principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.</p>
<div class="lb-trans"><p>MiMedx 的主要产品包括以 EpiFix®和 AmnioFix®等名称品牌的羊膜/绒毛膜同种异体移植物，适用于急性和慢性伤口的治疗，包括糖尿病足溃疡、静脉性腿部溃疡和手术部位修复。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than MiMedx Group</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
<li>The Biggest IPO Ever… Open to Everyday Folks</li>
<li>Silver records prices are great. Monthly income is better</li>
<li>Read this or regret it forever</li>
<li>Sell this, buy that</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票比 MiMedx Group 更好</li>
<li>用这 4 个简单步骤 “防止美联储影响” 你的银行账户</li>
<li>有史以来最大的 IPO……向普通人开放</li>
<li>银价记录很好，月收入更好</li>
<li>阅读此文，否则将永远后悔</li>
<li>卖这个，买那个</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURYRw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=MDXG"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in MiMedx Group Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 MiMedx Group 吗？</h2>
</div><p>Before you consider MiMedx Group, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 MiMedx Group 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiMedx Group wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 MiMedx Group 并不在名单上。</p>
</div><p>While MiMedx Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 MiMedx Group 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

MiMedx 集团（NASDAQ:MDXG）被华尔街 Zen 下调评级至买入